Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Hormone Replacement Therapy MarketThe global hormone replacement therapy (HRT) market is poised for steady growth, with a projected compound annual growth rate (CAGR) of 3.5%. From an estimated market ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The global Human Growth Hormone Powder Injection market is poised for immense growth, propelled by a surge in chronic diseases and the increasing prevalence ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The Mexico-based hormone clinic, which has online capabilities is doing its part to meet increased global demand for ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Listen to Story According to the latest World Bank report, India’s economic growth is projected to remain steady at 6.7% annually for the next two fiscal years, starting April 2025. India's growth ...